4503 N Stock Overview
Manufactures, markets, and imports and exports pharmaceuticals in Japan and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 3/6 |
Rewards
Risk Analysis
Astellas Pharma Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | JP¥204.11 |
| 52 Week High | JP¥204.11 |
| 52 Week Low | JP¥204.11 |
| Beta | 0.28 |
| 11 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -41.73% |
Recent News & Updates
Recent updates
Shareholder Returns
| 4503 N | MX Pharmaceuticals | MX Market | |
|---|---|---|---|
| 7D | 0% | -2.5% | -1.0% |
| 1Y | n/a | -17.5% | -3.3% |
Return vs Industry: Insufficient data to determine how 4503 N performed against the MX Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how 4503 N performed against the MX Market.
Price Volatility
| 4503 N volatility | |
|---|---|
| 4503 N Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 6.6% |
| Market Average Movement | 4.0% |
| 10% most volatile stocks in MX Market | 6.1% |
| 10% least volatile stocks in MX Market | 2.6% |
Stable Share Price: 4503 N has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine 4503 N's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1923 | 14,484 | Naoki Okamura | www.astellas.com |
Astellas Pharma Inc. manufactures, markets, and imports and exports pharmaceuticals in Japan and internationally. The company provides XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for patients who have relapsed or refractory acute myeloid leukemia with a FLT3 mutation; and PADCEV, a treatment for patients with metastatic urothelial cancer. It also offers Evrenzo, a treatment for anemia associated with chronic kidney disease; Betanis/Myrabetriq/BETMIGA, a treatment for overactive bladder; and Prograf and Advagraf/Graceptor/ASTAGRAF XL immunosuppressants.
Astellas Pharma Inc. Fundamentals Summary
| 4503 N fundamental statistics | |
|---|---|
| Market cap | Mex$303.45b |
| Earnings (TTM) | Mex$451.39m |
| Revenue (TTM) | Mex$165.94b |
672.3x
P/E Ratio1.8x
P/S RatioIs 4503 N overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 4503 N income statement (TTM) | |
|---|---|
| Revenue | JP¥1.54t |
| Cost of Revenue | JP¥281.54b |
| Gross Profit | JP¥1.26t |
| Other Expenses | JP¥1.26t |
| Earnings | JP¥4.20b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
Apr 25, 2024
| Earnings per share (EPS) | 2.34 |
| Gross Margin | 81.76% |
| Net Profit Margin | 0.27% |
| Debt/Equity Ratio | 58.1% |
How did 4503 N perform over the long term?
See historical performance and comparison